Promising New Data on Pediatric Use of Pretomanid in Children with Drug-Resistant Tuberculosis Presented at 2025 Union Conference
Positive results mark an important step forward in efforts to develop effective treatments for children…
Phase 2 Clinical Trial Results Show Potential to Shorten TB Treatment Time
Thuto Pulane, a TB survivor and participant in the NC-009 trial, at a follow-up appointment…
WHO Report Shows TB Gains, But Funding Gaps Threaten Momentum
TB Alliance is gratified to see clear progress against tuberculosis in the latest WHO Global…
Digital First, Faster Access: How TB Alliance Is Using Tech to Speed BPaL/M to People Who Need It
For decades, breakthrough TB science has too often moved slowly from approval to those in…
TB Alliance Launches Upskill TB Platform in Collaboration with Indonesia’s Ministry of Health and RPRI Foundation
Digital Training Platform, Upskill TB, Strengthens Capacity to Deliver New DR-TB Treatments JAKARTA (October 9,…
DR-TB Regimen Will Save 190,000+ Additional Lives and $1.29B by 2035
The six-month, all-oral BPaL/M regimens for the treatment of drug-resistant TB (DR-TB) are already changing…
New Report Finds Investing in Global Health R&D Delivers Returns at Home and Abroad
The investment case for global health R&D is increasingly evidence-based. Impact Global Health’s new Ripple…
New Study Finds Investing in Shorter, More Effective TB Treatment Pays Off
A new analysis, published in IJTLD Open, from South Africa and the Philippines further confirms…
TB Alliance Welcomes WHO Prequalification of Lupin’s Pretomanid Product
NEW YORK (September 12, 2025)—Lupin Limited, a leading pharmaceutical company headquartered in India, has been…